Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
The evolution of hematopoietic SCT in myelodysplastic syndrome
T. Kindwall-Keller
,
L. M. Isola
Research output
:
Contribution to journal
›
Review article
›
peer-review
39
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The evolution of hematopoietic SCT in myelodysplastic syndrome'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myelodysplastic Syndrome
100%
Hematopoietic SCT
100%
Myeloablative
40%
Chronic Graft-versus-host Disease (cGVHD)
40%
Matched Unrelated Donor
40%
Transplantation
20%
Relapse Risk
20%
Disease-free Survival
20%
Umbilical Cord Blood
20%
Nonmyeloablative
20%
Curative Treatment
10%
Patient Selection
10%
Published Results
10%
Medical Therapy
10%
Induction Therapy
10%
Hypomethylating Agents
10%
Reduced-intensity Conditioning
10%
Azacitidine
10%
Decitabine
10%
Donor Selection
10%
Transplantation Conditioning
10%
Recipient Age
10%
Supportive Therapy
10%
Prognostic Scoring System
10%
Myelodysplasia
10%
WHO Classification
10%
International Prognostic Scoring System
10%
Alternative Donor
10%
Age Cutoff
10%
Allografting
10%
Unanswerable Questions
10%
Nursing and Health Professions
Myelodysplastic Syndrome
100%
Graft Versus Host Reaction
36%
Disease Free Survival
18%
World Health Organization
18%
Scoring System
9%
Donor Selection
9%
Patient Selection
9%
Decitabine
9%
Angiographic Catheter
9%
Azacitidine
9%
Alternative Donor
9%
International Prognostic Scoring System
9%
Economic and Social Development
9%
Biochemistry, Genetics and Molecular Biology
Disease Free Survival
100%
Decitabine
50%
Azacitidine
50%
Donor Selection
50%
Medicine and Dentistry
Myelodysplastic Syndrome
100%
Graft Versus Host Reaction
36%
Disease Free Survival
18%
Cord Blood
18%
Patient Selection
9%
Scoring System
9%
Azacitidine
9%
Decitabine
9%
Donor Selection
9%
International Prognostic Scoring System
9%
Alternative Donor
9%
Immunology and Microbiology
Graft-Versus-Host Disease
100%
Umbilical Cord Blood
50%
Disease Free Survival
50%
Donor Selection
25%